home / stock / sybx / sybx quote
Last: | $1.65 |
---|---|
Change Percent: | -0.32% |
Open: | $1.6853 |
Close: | $1.65 |
High: | $1.72 |
Low: | $1.65 |
Volume: | 10,283 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.65 | $1.6853 | $1.65 | $1.72 | $1.65 | 10,283 | 05-17-2024 |
$1.68 | $1.69 | $1.68 | $1.77 | $1.68 | 6,233 | 05-16-2024 |
$1.72 | $1.7551 | $1.72 | $1.79 | $1.65 | 131,498 | 05-15-2024 |
$1.75 | $1.73 | $1.75 | $1.78 | $1.73 | 82,571 | 05-14-2024 |
$1.8 | $1.78 | $1.8 | $1.8378 | $1.78 | 2,681 | 05-13-2024 |
$1.79 | $1.83 | $1.79 | $1.83 | $1.79 | 7,123 | 05-10-2024 |
$1.83 | $1.88 | $1.83 | $1.88 | $1.8206 | 6,680 | 05-09-2024 |
$1.825 | $1.87 | $1.825 | $1.87 | $1.82 | 3,474 | 05-08-2024 |
$1.84 | $1.86 | $1.84 | $1.89 | $1.84 | 3,385 | 05-07-2024 |
$1.84 | $1.82 | $1.84 | $1.91 | $1.82 | 13,763 | 05-06-2024 |
$1.84 | $1.8301 | $1.84 | $1.9 | $1.81 | 29,923 | 05-03-2024 |
$1.88 | $1.8523 | $1.88 | $1.8866 | $1.8 | 6,055 | 05-02-2024 |
$1.9 | $1.86 | $1.9 | $1.9 | $1.8045 | 7,712 | 05-01-2024 |
$1.79 | $1.8254 | $1.79 | $1.845 | $1.78 | 20,571 | 04-30-2024 |
$1.87 | $1.95 | $1.87 | $1.95 | $1.82 | 8,133 | 04-29-2024 |
$1.87 | $1.8798 | $1.87 | $1.88 | $1.84 | 3,846 | 04-26-2024 |
$1.86 | $1.855 | $1.86 | $1.9 | $1.85 | 4,043 | 04-25-2024 |
$1.87 | $1.91 | $1.87 | $1.91 | $1.87 | 18,899 | 04-24-2024 |
$1.91 | $1.85 | $1.91 | $1.96 | $1.85 | 66,027 | 04-23-2024 |
$1.84 | $1.86 | $1.84 | $1.941 | $1.79 | 21,787 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, t...
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company...